Blockchain Registration Transaction Record

Daily Pill Matches Injectables in Cutting Bad Cholesterol by 60%

New daily oral medication enlicitide reduces LDL cholesterol by 60%, matching injectable PCSK9 inhibitors. Study presented at American Heart Association Scientific Sessions 2025 shows promise for high-risk patients.

This development matters because cardiovascular disease remains the leading cause of death worldwide, and many patients struggle to achieve target cholesterol levels despite existing treatments. The availability of an oral medication that matches the effectiveness of injectable PCSK9 inhibitors could dramatically improve treatment adherence and accessibility for millions of people at risk of heart attacks and strokes. For patients who find injections inconvenient, intimidating, or difficult to administer, this represents a potential breakthrough in managing their cardiovascular health more comfortably while still achieving the same level of protection. This could significantly reduce the burden of cardiovascular events and improve quality of life for high-risk individuals who currently have limited options beyond injectable therapies.